Document Detail

In vivo evaluation of a biolimus eluting nickel titanium self expanding stent with overlapping balloon expandable drug eluting and bare metal stents in a porcine coronary model.
MedLine Citation:
PMID:  19284078     Owner:  NLM     Status:  MEDLINE    
AIMS: Long lesions and complex vessel anatomy frequently require the use of overlapping stents to treat a lesion. The purpose of this study was to evaluate the long-term effects of overlapping the Axxess Biolimus A9 eluting stent (BES) with two of the most commonly used, commercially available drug eluting stents. These stents were compared to BxVelocity bare metal (BMS) stents in a porcine coronary stent-injury model. METHODS AND RESULTS: Nineteen juvenile farm swine, 25-35 kg in weight, 3-6 months in age were utilised. Each animal received an Axxess stent to their coronary artery as permitted by the individual animal's anatomy. A second stent, either a Cypher, sirolimus eluting stent (SES) or, a Taxus, paclitaxel eluting stent (PES), or a BxVelocity bare metal stent (BMS) were implanted in an overlapped fashion. The animals were then followed for either 28 or 180 days as specified by a randomisation scheme. At the end of each follow-up period, they were euthenised, and the vessels containing the overlapping stents were harvested, processed into histological sections, and analysed. Compared to bare metal stents, overlapped segments using DES exhibited delayed vascular healing compared to both the proximal and distal non-overlap sites at each of the follow-up time point. Overall, in the non-overlap stent segments, SES induced significantly more inflammation and neointimal hyperplasia compared to PES and BMS. CONCLUSIONS: In this study of BMS and two different types of DES overlapped with the Axxess Biolimus A9 eluting stent, we found that while there was a delay in the degree of vascular healing with DES compared to BMS, the specific type of DES that was overlapped with BES did not affect the behaviour of the overlap zone in terms of most of the histomorphometric measures at 28 or 180 days. This was true whether the stent was drug eluting or bare metal. More inflammation with delayed healing was seen in the SES compared to PES and BMS.
Mehmet Cilingiroglu; James Elliott; Pramod Sangi; Holly Matthews; Fermin Tio; Brett Trauthen; John Elicker; Steven R Bailey
Related Documents :
16488708 - Management of congenital and acquired pulmonary vein stenosis.
17897738 - Spontaneous resolution of multiple coronary aneurysms complicating drug eluting stent i...
16893698 - Effect of everolimus-eluting stents in different vessel sizes (from the pooled future i...
9023168 - Angiographic predictors of neointimal thickening after successful coronary wall healing...
9484928 - Alternative insertion sites for permanent central venous access devices.
18372438 - Fibromuscular dysplasia of the internal carotid circulation: an unusual presentation.
Publication Detail:
Type:  Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology     Volume:  4     ISSN:  1774-024X     ISO Abbreviation:  -     Publication Date:  2009 Jan 
Date Detail:
Created Date:  2009-03-16     Completed Date:  2009-03-26     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101251040     Medline TA:  EuroIntervention     Country:  France    
Other Details:
Languages:  eng     Pagination:  534-41     Citation Subset:  IM    
Division of Cardiology, Department of Medicine, Janey Briscoe Center for Cardiovascular Research, University of Texas Health Science Center in San Antonio, TX 78229-3900, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angioplasty, Transluminal, Percutaneous Coronary / adverse effects,  instrumentation*
Cardiovascular Agents / administration & dosage*
Cell Proliferation
Coronary Angiography
Coronary Vessels / drug effects,  pathology*
Drug-Eluting Stents*
Inflammation / etiology,  pathology
Models, Animal
Paclitaxel / administration & dosage
Platelet Aggregation Inhibitors / pharmacology
Prosthesis Design
Sirolimus / administration & dosage,  analogs & derivatives*
Time Factors
Wound Healing
Reg. No./Substance:
0/Biolimus A9; 0/Cardiovascular Agents; 0/Platelet Aggregation Inhibitors; 12035-60-8/titanium nickelide; 33069-62-4/Paclitaxel; 53123-88-9/Sirolimus; 7440-02-0/Nickel; 7440-32-6/Titanium

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Current and future developments in intracoronary optical coherence tomography imaging.
Next Document:  Coronary steal with unstable angina secondary to a coronary artery fistula.